<SEC-DOCUMENT>0001213900-24-090982-index.html : 20241028
<SEC-HEADER>0001213900-24-090982.hdr.sgml : 20241028
<ACCEPTANCE-DATETIME>20241028083510
ACCESSION NUMBER:		0001213900-24-090982
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241028
FILED AS OF DATE:		20241028
DATE AS OF CHANGE:		20241028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		241398536

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0218396-6k_neurosense.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea0218396-6k_neurosense.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021839601ex99-1_neuro.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 28, 2024, ENTITLED "NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION."
<TEXT>
Document 2 - file: ea021839601ex99-1_neuro.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 3 - file: ex99-1_001.jpg

</DOCUMENT>
</SEC-DOCUMENT>